The mission of the Cancer Vaccine Center is to develop therapeutic vaccines that will enable a person's immune system to destroy cancers. The Center pioneers technologies, integrates immunologic research with translational science, and tests vaccine candidates in clinical trials to create effective cancer vaccines. To accelerate the pace of scientific and clinical progress and to facilitate collaboration, the Center also provides expertise, consultation, and service in areas critical to the development of successful cancer vaccines. Key Center technologies include bioinformatics, nanotechnologies, mass spectrometry, structural biology, immune assessment, immunoproteomics, and immunogenomics. The Center maintains an integrated program of scientific discovery, preclinical vaccine development, and clinical investigation.
Scientific discovery efforts include:
- Selecting cancer vaccine targets for individual cancers
- Analyzing the immunogenicity of T-cell and B-cell peptide epitopes and performing cytokine immune assessments to identify epitopes and cytokines that enhance immune responses
- Examining methods for sustaining tumor immunity.
Preclinical vaccine development and clinical investigation efforts include:
- Using antigen- and cell-based efforts in allogeneic and autologous vaccine strategies for durable, broadly effective, anti-tumor responses
- Assessing the impact of adoptively transferring immune effector cells
- Exploring the use of antibodies directed at surface components of tumors and as blockers of negative immunoregulatory mechanisms that impede immunotherapy
- Evaluating the application of nanoscale devices for the development of nanotechnology-based vaccines, including directed delivery of immune stimulants and antigens.